Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2020009081
Abstract: Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent, Azacytidine, achieves complete response with or without count recovery in approximately 70% of treatment-naïve elderly patients unfit for conventional intensive chemotherapy. However, the mechanism of… read more here.
Keywords: venetoclax; cell mediated; enhances cell; venetoclax enhances ... See more keywords